ORGO
Organogenesis Holdings Inc.
ORGO trails on the overall score without a compensating advantage in the available component scores.
UNH
UnitedHealth Group Incorporated
UNH has the edge over ORGO overall, supported by stronger fundamentals and lower modeled downside.
ORGO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Strong |
ORGO's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ORGO PE Valuation
ORGO has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ORGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect ORGO's losses to shrink, with revenue declining.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over ORGO on the outlook, with more favorable revenue and profitability expectations.
ORGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.15 | -$1.04 |
| Q2 2026 | -$0.79 | -$0.66 |
| Q1 2026 | -$0.12 | +$0.04 |
| Q4 2025 | $0.15 | +$0.16 |
| Q3 2025 | -$0.11 | -$0.05 |
| Q2 2025 | -$0.13 | $0.00 |
| Q1 2025 | -$0.16 | -500% |
| Q4 2024 | -$0.01 | -125% |
ORGO lost $1.15 per share over the past year, and its loss has widened in each of the last three quarters.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ORGO on earnings quality, reporting a profit while its opponent remains loss making.
ORGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45.5M | -70% |
| Q2 2026 | $43.8M | -57% |
| Q1 2026 | $37.2M | -57% |
| Q4 2025 | $225.6M | +78% |
| Q3 2025 | $150.9M | +31% |
| Q2 2025 | $101M | -22% |
| Q1 2025 | $86.7M | -21% |
| Q4 2024 | $126.7M | +27% |
ORGO's revenue is shrinking: $45M last quarter, down 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -65% | -79 points |
| Q2 2026 | -117% | -104 points |
| Q1 2026 | -185% | -154 points |
| Q4 2025 | 28% | +20 points |
| Q3 2025 | 14% | +8.3 points |
| Q2 2025 | -12% | -1.8 points |
| Q1 2025 | -31% | -27 points |
| Q4 2024 | 8.1% | +9.3 points |
ORGO's operating margin was −65% last quarter, down 79 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over ORGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ORGO on profitability, with a higher operating margin.
ORGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.1M | -2477% |
| Q2 2026 | -$32.8M | +$3.8M |
| Q1 2026 | $18M | +$41.5M |
| Q4 2025 | $34.8M | +359% |
| Q3 2025 | $844K | -86% |
| Q2 2025 | -$36.5M | -1378% |
| Q1 2025 | -$23.6M | -$11.2M |
| Q4 2024 | $7.6M | +3.9% |
ORGO's free cash flow was −$64,000 over the past year, against −$52M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ORGO on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +316K shares |
| 1 year | -1.4% | -1.9M shares |
| 3 years | -3.3% | -4.4M shares |
| 5 years | -3.6% | -4.9M shares |
| Available history | +39% | +36.2M shares |
ORGO has the edge over UNH on shareholder dilution, with a more favorable share count trend.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ORGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -4.9x | Net Cash |
| Q4 2025 | -1.6x | Net Cash |
| Q3 2025 | -9.9x | Net Cash |
| Q4 2024 | -10.2x | Net Cash |
| Q3 2024 | -13.6x | Net Cash |
| Q2 2024 | -6.0x | Net Cash |
| Q1 2024 | -0.8x | Net Cash |
| Q4 2023 | -1.3x | Net Cash |
ORGO has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ORGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.3 | Oversold |
| Stochastic | 7.8 | Oversold |
ORGO's weekly RSI is 27 (oversold) and its Stochastic is 8 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ORGO PE vs Healthcare Sector
| Metric | ORGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ORGO has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ORGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.07 | 10% below |
| 20 week MA | $1.63 | 41% below |
| 50 week MA | $2.60 | 63% below |
| 100 week MA | $3.40 | 72% below |
| 200 week MA | $3.18 | 70% below |
ORGO is in a downtrend: it's below all five of its weekly moving averages, and 70% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ORGO on trend strength, trading above more of its moving averages.
ORGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.94 | $6.46 | +31% |
| 2021 | $6.46 | $10.2 | +58% |
| 2022 | $10.2 | $2.59 | -75% |
| 2023 | $2.59 | $4.09 | +58% |
| 2024 | $4.09 | $3.19 | -22% |
| 2025 | $3.19 | $5.28 | +66% |
| 2026 YTD | $5.28 | $0.96 | -82% |
ORGO is down 82% so far in 2026, after finishing higher in four of the previous six years.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ORGO on returns for 2026, with the stronger performance.